Last Updated | 31 March 2026

REACH2

A Phase III Randomized Open-Label Multi-centre Study of Ruxolitinib versus best available therapy in patients with Corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation
External Registry
Site Status
Queensland Children's Hospital (QLD)
John Hunter Children's Hospital (NSW)
Sydney Children's Hospital (NSW)
Monash Health Clayton (VIC)
Royal Children's Hospital (VIC)
Women's and Children's Hospital (SA)
Perth Children's Hospital (WA)
Royal Hobart Hospital (TAS)
Children's Hospital at Westmead (NSW)
Starship Children's Hospital (NZ)
Christchurch Hospital (NZ)
Preparing to Open
Open
Temporarily Closed
Closed
Complete
Adult Sites These sites are not monitored. Status may vary.
Diagnosis Stage Previously Treated
National Sponsor Novartis Pharmaceuticals
Open Date 10/03/2017
Conditions Corticosteroid Refractory Acute Graft vs Host Disease
Patient Range >12 years
Disease Type Leukaemia / Lymphoma / Blood Disorders
Study Type Interventional
International Sponsor N/A

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.